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Abstract:  Chronic  obstructive  pulmonary  disease  (COPD)  is  characterized  by  an 
abnormal and chronic inflammatory response in the lung that underlies the chronic airflow 
obstruction of the small airways, the inexorable decline of lung function, and the severity 
of the disease. The control of this inflammation remains a key strategy for treating the 
disease;  however,  there  are  no  current  anti-inflammatory  treatments  that  are  effective. 
Although glucocorticoids (GCs) effectively control inflammation in many diseases such 
as asthma, they are less effective in COPD. The molecular mechanisms that contribute 
to the development of this relative GC-insensitive inflammation in the lung of patients 
with COPD remain unclear. However, recent studies have indicated novel mechanisms 
and possible therapeutic strategies. One of the major mechanisms proposed is an oxidant-
mediated alteration in the signaling pathways in the inflammatory cells in the lung, which 
may result in the impairment of repressor proteins used by the GC receptor to inhibit the 
transcription of proinflammatory genes. Although these studies have described mechanisms 
and targets by which GC function can be restored in cells from patients with COPD, more 
work is needed to completely elucidate these and other pathways that may be involved in 
order to allow for more confident therapeutic targeting. Given the relative GC-insensitive 
nature of the inflammation in COPD, a combination of therapies in addition to a restoration 
of GC function, including effective alternative anti-inflammatory targets, antioxidants, and 
proresolving therapeutic strategies, is likely to provide better targeting and improvement in 
the management of the disease.
Keywords: inflammation, oxidative stress, histone deacetylase, phosphoinositol 3-kinase, p38 
mitogen-activated protein kinase
Definition and prevalence
Chronic obstructive pulmonary disease (COPD) is a disease of the lungs where there 
is an abnormal chronic inflammatory response.1 This is associated with remodeling 
and narrowing of the small airways, which results in airflow limitation and a gradual 
inexorable decline of lung function that is not fully reversible and is progressive.2,3 
COPD is usually diagnosed in the clinic by a postbronchodilator forced expiratory 
volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of ,70% and a FEV1 
of $80% predicted.3,4 According to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines, COPD severity can be categorized into 4 stages (I–IV) 
on the basis of FEV1 (Table 1).3 COPD is considered a preventable and treatable 
disease in which there may be some significant extrapulmonary effects that may also 
contribute to the severity of the disease in individual patients.3International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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The abnormal inflammatory response in the lungs of 
patients with COPD is usually considered to be the result 
associated with exposure to noxious particles or gases such as 
those contained in cigarette smoke, which is   recognized as the 
main etiological factor associated with the development of 
COPD.1,4 However, cigarette smoking does not fully explain 
variations in disease prevalence; therefore, other risk factors 
are likely to be involved, such as exposure to fossil fuels and 
environmental traffic pollution.5 One of the important fea-
tures of the disease is that the chronic inflammatory response 
in the lung often persists even when the main exogenous 
driving factor such as cigarette smoke has been removed. 
This apparent self-perpetuation of the chronic inflammatory 
response may contribute to the continuous decline of lung 
function and subsequent progression of the disease.1,6,7
COPD is a leading cause of morbidity and mortality. 
Although the incidence of cigarette smoking in the western 
world is decreasing, as the population ages, the incidence 
of COPD is likely to increase before decreasing given the 
latent nature of the disease. Furthermore, cigarette smoking 
is increasing in densely populated developing nations such 
as China, which will further enhance the global burden 
of the disease. The World Health Organization (WHO) 
  estimated that 3 million people died of COPD in 2005, and 
there were approximately 210 million people with COPD 
in 2007.8   Currently, COPD is the fifth most common cause 
of mortality worldwide, but total deaths due to the disease 
are predicted to rise by 30% in the next 10 years.8 COPD 
is now predicted to become the third leading cause of death 
worldwide by around 2030.8
Pathophysiology
COPD is a complex disease and is often used as an “umbrella” 
term to incorporate 3 distinct disease processes, chronic 
  bronchitis, emphysema, and small airways disease, which 
may be present in varying degrees and contribute to the 
  airflow obstruction.1 It is worth noting that chronic   bronchitis 
is usually defined by the symptoms of cough and sputum 
  production over the winter months, and this usually may or 
may not be associated with any indices of airflow   obstruction. 
The increased mucus production due to   submucosal 
gland hypertrophy and hyperplasia in chronic bronchitis 
coupled with the reduction in mucociliary   clearance seen 
in patients with COPD is a major contributing factor in 
bacterial   colonization and infections, which contributes to 
exacerbations.1,9,10 The destruction of the parenchyma and 
enlargement of the alveoli and alveolar ducts distal to the 
terminal bronchioles termed “emphysema” are likely to 
contribute to airflow limitation because of a loss of the lung 
elastic recoil.11 The degree of airflow limitation (as measured 
by FEV1) is correlated with the degree of wall thickening 
of the small airways, providing evidence of a role for small 
airway remodeling in the airflow obstruction in COPD.2 
The decline of lung function and the severity of the disease 
correlated with the degree of narrowing of the small airways 
but not with the degree of emphysema or chronic bronchitis 
present.2 This suggests that the narrowing of the small airway 
may be a predominant factor in the development of airflow 
limitation in COPD.
The degree of inflammation in the lungs of patients with 
COPD increases with the severity of the disease.2 The inflam-
mation is characterized by an accumulation of neutrophils, 
macrophages, B cells, lymphoid aggregates, and CD8+ T cells, 
particularly in the small airways.1,6,12 This is likely to represent 
both innate and adaptive immune responses to the toxic particles 
and gases.13 This inflammation is orchestrated by a complex 
milieu of proinflammatory mediators, including chemokines, 
such as CCL2, CXCL1, and CXCL8 (11); cytokines, such as 
tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and 
interferon (IFN)-γ; and proteases, such as neutrophil elastase 
and metalloproteinase-9.7 As the severity of COPD advances, 
there is an increase in the numbers of B cells, which may 
indicate an adaptive immune component to the inflammatory 
response in the later stages of COPD.2,14 Autoimmunity may 
also play a role in COPD, in particular, caused by cigarette 
smoke-damaged proteins, with autoantibodies, including anti-
elastin, antiepithelial, and tobacco anti-idiotypic antibodies, 
detected in smoking patients with COPD.15–17
Table 1 GOLD stages of chronic obstructive pulmonary disease 
severity
COPD  
severity
Characteristics
FEV1/ 
FVC
FEV1
GOLD Stage I 
(mild)
,70% –
GOLD Stage II 
(moderate)
,70% ,50%–70%
GOLD Stage III 
(severe)
,70% ,30%–50%
GOLD Stage Iv 
(very severe)
,70% ,30% or ,30%–50% with respiratory 
insufficiency (defined as PaO2 , 60 mmHg 
and/or PCO2 , 50 mmHg while breathing 
air at sea level)
Abbreviations:  GOLD,  global  initiative  for  chronic  obstructive  lung  disease; 
COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 
1 sec; FvC, forced vital capacity; PaO2, partial pressure of oxygen in arterial blood; 
PCO2, partial pressure of carbon dioxide.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Some inflammatory cells also appear to be   functionally 
altered in COPD, which is likely to contribute to the patho-
genesis and progression of the disease. In particular, the 
phagocytic ability of both neutrophils and macrophages 
is reduced, which is likely to contribute to the ineffective 
control of bacterial colonization and clearance of dead cells, 
respectively.18–20 Impairment in the clearance of dead and 
damaged cells is also likely to contribute to the enhancement 
and chronic nature of the inflammatory response.
Glucocorticoid treatment in COPD
The abnormal chronic inflammation in the lung of patients 
with COPD is widely recognized as a prominent driving 
force in the progression of the disease. However, no current 
anti-inflammatory treatments significantly modify the chronic 
inflammatory response or the decline of lung function.
Inhaled glucocorticoids
Although both inhaled and oral glucocorticoids (GCs) are 
effective at controlling inflammatory lung diseases such as 
asthma, their effectiveness is substantially less in COPD; 
therefore, their contribution to the management of stable 
COPD is limited.3,21 Results published from the TOwards 
a Revolution in COPD Health (TORCH) study of patients 
with COPD, with a FEV1 of ,60%, indicated that regular 
use of inhaled GCs may decrease the rate of decline of lung 
function.22 However, the majority of studies have concluded 
that the use of regular inhaled GCs has no impact on the 
long-term progressive decline in FEV1.23–26
Regular treatment with inhaled GCs may reduce the 
frequency of exacerbations of the disease in patients with 
severe (GOLD stage III) and very severe (GOLD stage IV) 
COPD.27–29 Regular inhaled GCs may also reduce dyspnea 
and thereby improve health status.30 In addition, withdrawal 
from inhaled GC treatment can lead to increased rates of 
exacerbations in some patients.31 However, treatment with 
inhaled GCs increases the risk of pneumonia and does not 
reduce the overall mortality.32–34 Therefore, although the 
majority of studies show that inhaled GCs have no impact 
on the progression of the decline of lung function, there 
is evidence that patients with more advanced (GOLD 
stage III or IV) COPD and repeated exacerbations may 
derive some benefit. A number of studies have also shown 
that a combination of long-acting β2-agonists (LABAs) and 
inhaled GCs is more effective than either treatment alone 
in reducing exacerbation frequency, improving lung func-
tion, and improving health status.29,30,32,35–38 Results from the 
TORCH study also indicated that a combination therapy of 
LABA and inhaled GC may reduce the rate of decline of lung 
function.22 However, similar to the effects of inhaled GC 
therapy alone, a combination therapy of LABAs and inhaled 
GCs also increases the likelihood of pneumonia and has no 
significant effect on overall mortality.32
Oral GCs
An early study suggested that short-term GC effects can pre-
dict long-term effects of GCs on FEV1; therefore, short-term 
use of oral GCs (2 weeks) could be recommended to assess 
if a patient was likely to benefit from long-term use of either 
inhaled or oral GC therapy.39 However, other recent studies 
indicate that short-term use of oral GCs is a poor predictor 
of long-term response to inhaled GCs.3,26,40 Consequently, 
GOLD guidelines do not recommend undertaking a thera-
peutic trial with oral GCs in patients with stage II (moderate), 
stage III (severe), or stage IV (very severe) COPD who have 
a poor response to an inhaled bronchodilator.3 The short-term 
response to oral course of prednisolone in terms of increased 
airway caliber and improved health-related quality of life can 
be predicted by the presence of sputum eosinophilia.41,42
Oral GCs provide benefit in the treatment of COPD exac-
erbations with a significant reduction in treatment failure and 
the need for additional medical treatment and shorter hospital 
stay.43 However, the benefits of oral GCs in the treatment 
of stable COPD are less evident and convincing given the 
minimal improvements in lung function and the long-term 
side effects of oral GC therapy.44 Therefore, although inhaled 
GCs do have some benefits in the treatment of COPD, par-
ticularly in advanced disease, their benefits are limited; both 
inhaled and oral GC therapies provide more benefit in acute 
exacerbations: the former prevents the exacerbation and the 
latter reverses it. However, the modest beneficial effect of 
inhaled GCs on the frequency of exacerbations has been 
questioned.45–47
GC insensitivity in COPD
The limited effectiveness of GC treatment in COPD com-
pared with other inflammatory lung conditions such as asthma 
has led to the concept that the inflammation in the lung of 
patients with COPD is relatively GC insensitive.21 In addition 
to having no impact on the decline of lung function, inhaled 
GCs have little effect on the numbers of inflammatory cell or 
on the release of proinflammatory mediators in the lungs of 
patients with COPD.48–50 This is reflected ex vivo where GCs 
fail to repress the release of proinflammatory mediators from International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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alveolar macrophages obtained from the bronchoalveolar 
lavage from patients with COPD.51
Development of GC insensitivity  
in COPD
Cellular mechanisms
The molecular mechanisms that contribute to the develop-
ment of a relative GC-insensitive inflammatory response in 
COPD remain unclear. First, there is an inherent variation in 
GC responsiveness between different cell types and tissues.52 
This may relate to the expression of the dominant negative 
glucocorticoid receptor (GR)β isoform, whose expression 
correlates with effective GC function in particular cells or 
tissues.52,53 However, the majority of the cells that make up 
the lung and the infiltrating inflammatory cells in COPD 
are largely responsive to GCs. In addition, other inflamma-
tory conditions involving many of these cell types are well 
controlled. It is therefore unlikely that an intrinsic relative 
GC unresponsiveness of a particular cell type or of the lung 
itself can fully account for the reduction of GC insensitivity 
seen in COPD.
One exception to this is neutrophils, where neutrophillic 
inflammation is relatively unresponsive to GC-mediated 
immunosuppression compared with other cell type predomi-
nant inflammation.45,54,55 Neutrophils are not only present in 
stable COPD but are the predominant infiltrating inflam-
matory cells in exacerbations of the disease, which are also 
controlled to a lesser extent by GCs.45 Some studies have 
suggested that this may be due to a relatively high expres-
sion of the dominant negative GRβ isoform.53 However, 
other studies have found low expression of GRβ; therefore, 
this concept is controversial, and the exact mechanisms 
behind the reduced effectiveness of GCs on neutrophilic 
inflammation remains unclear.56 It is also unclear whether 
the GC insensitivity during exacerbations is an extension of 
the existing GC insensitivity of stable COPD or if there is an 
additional unresponsiveness mediated by the acute elevation 
in neutrophils during the exacerbation.
The levels of GRβ expression have been assessed in 
COPD, but although the expression of GRα is reduced, 
there is no apparent change in the expression of GRβ.55,57 
It is   therefore feasible that a higher level of GRβ to GRα 
ratio in the lung or inflammatory cells in patients with 
COPD may impair GRα function enough to contributing to 
GC   insensitivity. However, with very few studies   assessing 
the relative expressions of GRα and GRβ in COPD and 
  importantly, any functional impact by an elevation in the 
ration of GRβ, it is difficult to assign a role for GRβ in 
the development of GC insensitivity with any confidence. 
Impairment of GRα translocation contributes to reduced 
GC responsiveness in some diseases, such as in a subset of 
patients with multiple sclerosis where an elevation of expres-
sion of heat shock protein 90 (Hsp90) results in increased 
sequestration of GRα to the cytosol.58 However, although 
there is evidence for an elevation of Hsp90 expression in 
COPD, and in some assays, oxidant stress can impair GRα 
translocation in vitro, currently, there is a lack of any compel-
ling in vivo or translational evidence of a role for impaired 
GRα translocation in COPD GC responsiveness.59,60
Genetics
A number of studies have linked genetic mutations with the 
development of GC insensitivity.52 In patients with asthma, 
11 genes have now been identified, which may discriminate 
between relative GC-insensitive and GC – sensitive patients 
with asthma, suggesting that there may be a genetic factor 
in the development of relatively GC-insensitive asthma.61 
A direct link between genetic mutations and the develop-
ment of relative GC insensitivity in COPD has not been 
established. However, there is evidence that genetic suscep-
tibility is likely to play a role in the development of COPD. 
Studies investigating the antioxidant capacity of the lungs 
of patients with COPD and smokers suggest that subjects 
that develop COPD have a reduced capacity to elevate their 
antioxidant defenses, which may, in part, account for the 
development of COPD in a subset of smokers (∼20%) rather 
than all smokers.62–64 Interestingly, the 213Gly variant of the 
antioxidant extracellular superoxide dismutase 3 (SOD3), 
which affects approximately 2% of the population, increases 
the plasma SOD3 levels 10-fold and has been associated with 
a protection in smokers to the consequent development of 
COPD.63,65 Furthermore, given the likely central role for oxi-
dant stress in the development of GC insensitivity (discussed 
in the following section), the reduced antioxidant capacity is 
also likely to contribute to the development of a relative GC 
insensitivity in COPD.
Oxidative stress
As the innate or helper T cell type 1 (TH1) inflammatory 
response is well documented as responding well to GCs, 
the enhanced and relatively GC-insensitive inflammatory 
cell present in the lungs of patients with COPD is likely to 
incorporate an underlying factor. One prominent theory is 
that an elevation in the oxidant burden in the lungs (termed 
“oxidative stress”) plays a central role in both the enhance-
ment of the inflammatory response and the development of International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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a relative GC insensitivity.1,66 This concept is supported by 
experimental and mechanistic evidence and is also in align-
ment with other proposed mechanisms including direct dis-
ruption of GRα corepressor activity and alteration of kinase 
signaling, discussed below.
The elevation in the oxidant burden in the lungs of patients 
with COPD may be derived both from exogenous sources, 
such as pollution and cigarette smoke, and   endogenous 
sources, such as respiratory burst of proinflammatory cells, 
such as macrophages and neutrophils. Physiologically, 
  oxidants and the redox state of the cell are an integral part 
of cellular signaling and function including that of GRα.67,68 
However, a significant elevation in the oxidants can over-
come both intracellular and extracellular antioxidant defenses 
leading to significant alterations in signaling pathways and 
protein function.69 The role of exogenous oxidative stress 
derived from cigarette smoke is highlighted by its induction 
of reduced GC insensitivity in experimental models and the 
development of relative GC insensitivity in mild or moderate 
asthma patients who smoke.1,55,70,71
Oxidant stress: HDAC  
and corepressor function
A central factor in both an oxidant-mediated enhancement 
of inflammatory responses and development of relative GC 
insensitivity may be facilitated by a direct alteration in the 
acetylation–deacetylation balance of the core histone pro-
teins.72,73 A central part of GRα function is the recruitment 
of corepressor complexes containing histone deacetylases 
(HDACs), which remove acetyl groups from the NH-terminal 
tails of core histone proteins.73–75 These acetyl groups on 
the histone tails confer a “relaxed” transcriptionally open 
structure to the promoter region of the genes, and their 
removal results in reassociation of the DNA around the core 
histones and gene silencing.73,74,76 In vitro studies using small 
interfering RNA and overexpression models have shown 
that HDAC-2 is the key in the functional mechanism of 
GC-mediated or GRα-mediated histone deacetylation and 
gene repression.77
Acutely, oxidative stress reduces HDAC-2 activity with 
a reduction in HDAC-2 protein expression seen with more 
chronic oxidant exposures in in vitro and in vivo models.71,78,79 
This reduction in HDAC-2 activity and expression is strongly 
associated with oxidant-mediated covalent modifications, 
including hyperphosphorylation, nitration, and carbonyla-
tion, which impair protein activity and enhance proteasomal 
degradation.72,73,78–83 These modifications are mediated by 
reactive oxygen, including reactive carbonyls and reactive 
nitrogen species, and by kinase signaling pathways activated 
by oxidant stress.72,73,83 Although the exact mechanisms and 
pathways that regulate these modifications remain unclear, 
recent work has suggested that oxidants modulate HDAC-2 
phosphorylation and subsequent ubiquitination followed 
by proteasomal degradation through a protein kinase 
CK2α-dependant mechanism.84,85
The acetylation – deacetylation balance of histone is a 
highly regulated process and central in the control of gene 
transcription.74 Therefore, this oxidant-mediated loss of 
HDAC-2 activity and resulting imbalance in histone acety-
lation status are likely to contribute to the enhanced inflam-
matory responses in this disease. In agreement with this, 
HDAC-2 activity and expression are reduced in the peripheral 
lungs of patients with COPD, which correlate with disease 
severity.86 Furthermore, as HDAC-2 activity is   fundamental 
for functional GRα transrepression of proinflammatory 
genes, a reduction in its activity and expression is lightly to 
impair GC function and thereby contributes to a reduction 
in GC responsiveness (Figure 1). Similarly, in models where 
HDAC-2 activity is compromised, GC function is reduced, 
and restoration or protection of HDAC-2 activity is correlated 
with a restoration in GC sensitivity.55,87 Therefore, there is 
strong evidence that the reduction in HDAC-2 activity and 
expression seen in patients with COPD is likely to be an 
important factor in the mechanisms of the relative GC insen-
sitivity in this disease. In addition, as there is a reduction in 
expression of other HDACs in COPD, including HDAC-3, 
5, and 8, it must also be considered that the alteration in the 
expression and/or activity of other HDACs may also play 
a role in the impairment of GC function.86 Cigarette smoke 
exposure results in a reduction of HDAC-1, 2, and 3 in the 
macrophage cell line, Mono Mac 6 cells, associated with 
elevated tyrosine nitration and aldehyde adduct formation.88 
However, the roles of these HDACs in the lung and inflam-
matory cells involved in COPD are poorly understood, and 
studies are needed to clarify their roles in GR function and 
in disease.
Kinase signaling
Kinase signaling is integral to the orchestration of the 
  inflammatory response.89 However, some of these kinase 
pathways are elevated in COPD and may also play a 
role in the development of GC insensitivity in the disease. 
The expression of p38 mitogen-activated protein kinase 
(MAPK) is elevated in the peripheral lungs and alveolar 
  macrophages in patients with mild or moderate COPD 
compared with smokers.90 This study also suggested   International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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an inverse correlation between the activation of p38 
MAPK and the reduction in FEV1 and FEV1/FVC.90 An 
  elevation of p38 MAPK may be responsible for an increase 
in   phosphorylation of GRα in a manner that results in a 
  reduction of its ligand-binding ability.91 A negative feedback 
mechanisms used by GCs to regulate the inhibitory effect of 
p38 MAPK on GRα in an induction of MAPK phosphatase-1 
(MKP-1) expression, which reduced p38 MAPK activity by 
  dephosphorylation (REF). A study looking at patients with 
severe asthma vs nonsevere asthma found a reduction in the 
  dexamethasone-  induced expression (messenger RNA) of 
MKP-1 and   elevation in p38 activity in patients with severe 
asthma compared with patients with nonsevere asthma.92 
However, no studies have looked at the GC-mediated induc-
tion of MKP-1 in COPD, and consequently no links have yet 
been made between the expression, activity, or signaling of 
MKP-1 and the reduction in GC responsiveness in COPD, 
although the potential is clearly explained.
There is also increasing evidence that a plethora of other 
kinases and signaling pathways, including glycogen synthase 
kinase-3β, extracellular signal-regulated kinase-1/2, and 
c-Jun N-terminal kinase, can directly regulate the activity 
of GRα through phosphorylation and thereafter may also 
influence its gene specificity.93,94
Oxidant stress also activates various kinase pathways, 
including the phosphoinositide 3-kinase (PI3K)/Akt path-
way through selective activation of the PI3Kδ isoform 
(Figure 1).95,96 Our recent study has shown that the activation 
of both PI3Kδ and Akt is elevated in macrophages from the 
peripheral lungs of patients with COPD.96 Specific inhibi-
tion of PI3Kδ/Akt signaling pathway restores and protects 
both HDAC-2 activity and GC function in oxidant-mediated 
GC-insensitive models.55 Similarly, selective inhibition of 
PI3Kδ/Akt pathway restores the ability of GCs to repress 
inflammatory mediator expression in patients with COPD 
comparable to smokers with normal lung function.96 
Cigarette smoke/pollution
Inflammatory cell respiratory burst
Oxidative stress
+
+
Increased PI3Kδ
signalling
Corepressor
complex
Corepressor
complex
Elevated proinflammatory
gene expression
Antioxidant gene expression
Genetic susceptibility: Impaired
antioxidant defence capacity
Nrf2
Oxidants
Antioxidants
GRα
p50
p65
GRα
HDAC-2
HDAC-2
Figure 1 Simplified diagrammatic representation of the mechanisms involved in an oxidant-mediated relative reduction of GC sensitivity. Oxidative stress generated by both 
exogenous and endogenous sources can directly (nitration and aldehyde adduct formation) and indirectly (PI3Kδ/Akt signaling) impair key transcriptional repressor proteins 
utilizing the GRα including HDAC-2, thus preventing GC-mediated repression of proinflammatory mediators. If the antioxidant defense response is impaired, this oxidant 
imbalance results in elevated inflammatory mediator expression, which GC is unable to repress.
Abbreviations: GC, glucocorticoid; PI3K, phosphoinositide 3-kinase; GR, glucocorticoid receptor; HDAC, histone deacetylase; Nrf2, NF-e2-related factor 2 (a major 
regulator of antioxidant gene expression).International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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However, although the mechanism by which inhibition 
on PI3Kδ protects GC function appears to be mediated 
through the protection of HDAC-2 activity, it is also likely 
to include modulation of other corepressors, such as Mi-2 
and mSin3a.55,97 The mechanism by which PI3Kδ affects 
HDAC-2 activity and GRα function appears to involve 
oxidant-mediated covalent modifications, including tyrosine 
nitration and hyperphosphorylation induced by the oxidative 
stress.55 However, the mechanisms and pathways that elicited 
downstream of PI3Kδ/Akt signaling during oxidant stress, 
which facilitates the modification of HDAC-2 and expression 
of other corepressors, remain unclear.
Strategies for overcoming GC 
insensitivity in COPD
Restoration of GC function
GCs provide an effective treatment for the control of both 
acute and chronic inflammation in many diseases. Their 
delivery, side effects, and drug–drug interactions are all well 
characterized; therefore, the ability to restore the function 
of GC in COPD is a favorable strategy. The methylxanthine 
theophylline has been shown to provide a GC “sparing” effect 
when given at a low concentration with GCs.98 A low dose of 
theophylline may also improve the anti-inflammatory action 
of GC in an exacerbation of COPD.99 However, the exact 
mechanism of this GC “sparing” action is unclear. Theophyl-
line is often described as a phosphodiesterase (PDE) inhibi-
tor but is also known to have many “off-target” interactions 
including gene regulation.100 Importantly, the concentrations 
that can achieve this GC sparing are below the concentration 
at which it targets PDE. This is further complicated by an 
interesting observation that the binding profile of theophyl-
line is significantly different in cells that have been exposed 
to oxidative stress and is therefore likely to be different in 
patients with COPD and those with their higher oxidant 
burden in lung.100,101 Although the exact direct molecular 
targets of theophylline that confer this GC sparing or enhanc-
ing activity remain unresolved, the downstream mechanism 
involves the restoration of HDAC activity.87,102,103
In addition to theophylline, the curcumin, a polypheno-
lic natural compound, has also demonstrated an ability to 
restore GC function in vitro.104,105 Similar to theophylline, the 
curucmin-mediated restoration of GC function is proposed 
to work through a protection of HDAC-2 expression and 
activity.79 However, as with theophylline, curcumin has a 
seemingly wide and relatively nonspecific action at a range 
of concentrations including activation and repression of sev-
eral kinases and transcription factors. Although functionally 
it has been documented as antioxidant, anti-inflammatory, 
and GC protective, the precise molecular targets for these 
specific actions may be difficult to elucidate, and further 
studies into the precise molecular effectors of its actions 
are required.106
Selective inhibition of PI3Kδ also restores the   ability 
of GCs to repress inflammatory mediator expression, 
which appears to be through protection and/or restoration 
of HDAC-2 activity.55 This similarity between the reported 
mechanisms may indicate that theophylline may be medi-
ated its action through inhibition of the PI3Kδ pathway, but 
although theophylline does inhibit various PI3K isoforms 
at high concentrations, a direct link at a low concentration 
in oxidant-stressed cells has yet to be made.100 The PI3Kδ 
and γ isoforms are also relatively leukocyte specific and are 
central in the orchestration of both the innate and the adap-
tive immune responses, including neutrophil recruitment, 
high-affinity IgE receptor (FcεRI) signaling, and chemokine 
signaling.107–112 Selective PI3Kδ/γ inhibitors have received 
intense interest from the pharmaceutical industry and are 
being developed as anti-inflammatory drugs, particularly 
for allergic disease. Therefore, with selective PI3K isoform 
inhibitors currently under development, the targeting of 
PI3Kδ may be preferable to theophylline whose mechanism 
remains unclear and has no additional anti-inflammatory 
effect itself (Figure 2).
Alternative anti-inflammatory agents
Alternative anti-inflammatory targets have been proposed 
for COPD. TNF-α is a central mediator in the inflammatory 
response seen in the lungs of patients with COPD.7 However, 
a trial with the anti-TNF-α antibody infliximab determined 
that there was no benefit in moderate to severe COPD, and 
this was associated with severe adverse events, particularly 
cancer and lung infections.113 Selective p38 MAPKα inhibi-
tors are potent at suppressing the release of proinflammatory 
mediators in vitro including those closely associated with 
COPD, such as TNF-α and CXCL8.114,115 Selective inhibi-
tion of p38 MAPKα also suppresses oxidant-mediated 
lung inflammation in mice where GCs are not effective, 
indicating that the functional anti-inflammatory properties 
of p38 MAPK inhibitors are not adversely affected by oxi-
dant stress.116,117 The expression of p38 MAPK is elevated 
in the lungs of patients with COPD, and the selective 
inhibitors reduce the expression of inflammatory markers 
in the blood of patients with COPD.118 This suggests that 
selective targeting of p38 MAPK in COPD may provide a 
potentially effective alternative therapeutic strategy to GCs International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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(Figure 2), particularly that it may also enhance the effect 
of any   concomitant GC therapy. However, p38 MAPKα 
is important in many cell functions, and one major hurdle 
facing the development of selective p38 MAPKα inhibitors 
appears to be cytotoxicity.119
Proresolving strategies
A significant driving force behind an enhanced and persis-
tent inflammation may be an inability of the inflammation 
to resolve and thereby self-regulate. This is likely to be an 
integral factor in COPD where even after the removal of the 
exogenous driving force (predominantly, cigarette smoke), 
the inflammatory response continues. This impairment of 
inflammatory resolution may be particularly important in 
the context of GC treatment in COPD.
Although GCs are not effective at repressing neutrophilic 
inflammation, studies have shown that GCs can significantly 
impair the rate of constitutive apoptosis of neutrophils.120 
This constitutive cell death is an important “safety” feature 
of neutrophil function, which prevents a prolonged release 
of toxic and damaging agents, such as superoxide and 
neutrophil elastase, which may damage otherwise healthy 
tissue, thereby perpetuating the inflammatory response.121 
Controlled cell death termed “apoptosis” is a key feature of 
neutrophil cell death, as this prevents the release of the toxic 
and inflammatory contents of the dead cell and also targets 
the cell for phagocytosis and clearance by macrophages.121–123 
The nonphlogistic clearance of apoptotic neutrophils is also 
considered a central feature in inflammatory resolution, as 
it triggers a switch in the phenotype of the macrophages 
from proinflammatory to proresolving with the release 
of proresolving mediators, such as prostaglandin E2 and 
IL-10.121,124–126
Macrophage phagocytosis is impaired in COPD, which 
may be due to the effect of cigarette smoke, and there-
fore, the rate of the clearance of apoptotic neutrophils 
is likely to be reduced.127,128 If GC treatment of patients 
with COPD reflects what is seen in in vitro assays with a 
delay in neutrophil apoptosis, then the neutrophil may not 
only be living longer and releasing more inflammatory 
Figure 2 Possible therapeutic strategies for alternative effective anti-inflammatory drugs or for the additional restoration of GC function for an oxidant-mediated reduction 
in GC sensitivity. An effective antioxidant would combat one of the major contributing factors to the chronic and relatively GC unresponsive inflammation in COPD. 
Current therapies such as theophylline may be able to restore the effectiveness of GCs, thus allowing GC to be more effective in COPD. Oxidant-driven alterations in kinase 
signaling are likely to contribute to the impaired GRα function in COPD and selective targeting of these pathways, such as PI3Kδ and p38 MAPK, which could also restore 
the effectives of GC in COPD. In addition, alternative anti-inflammatory inhibitors, such as PI3Kδ/γ or p38 MAPK, may also provide effective alternative or combinatorial 
anti-inflammatory strategy to GCs in the oxidant-driven inflammation in COPD.
Abbreviations: GC, glucocorticoid; COPD, chronic obstructive pulmonary disease; GR, glucocorticoid receptor; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated 
protein kinase; JNK, c-Jun N-terminal kinase; GSK, glycogen synthase kinase; eRK, extracellular signal-regulated kinase; HDAC, histone deacetylase.
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agents but also be fueling the destruction of the lung and 
  inflammatory response by the release of its cellular contents 
through   necrosis due to its defective clearance by resident 
  macrophages. A few studies have looked into inflammatory 
resolution in COPD, and there is little direct information on 
the impact of GCs; however, this area may prove to be useful 
in finding potentially effective and novel anti-inflammatory 
drugs for COPD.
Interestingly, in addition to their role in initiation of 
both innate and adaptive immune responses and a potential 
role in the restoration of GC function, PI3Ks may also play 
an important role in the resolution of inflammation. The 
resolution or allergen-induced eosinophilic inflammation is 
enhanced by inhibition of PI3K by a mechanism involving 
blockade of Akt activation and enhanced cell apoptosis.129 
Studies using both transgenic mice and selective inhibitors 
have demonstrated that PI3Kβ is required for functional Fcγ 
receptor-mediated macrophage phagocytosis.130   Therefore, 
in addition to their anti-inflammatory action, selective 
PI3K inhibitors may also promote inflammatory resolution 
and thereby may provide an additional therapeutic benefit. 
A range of other small-molecule inhibitors that target the 
rate of neutrophil apoptosis has also been developed. These 
include inhibitors of cyclin-dependant kinases such as 
  roscovitine, which have recently been shown to promote 
neutophil apoptosis and inflammatory resolution in vivo.123 
Therefore, selective inhibitors that promote neutrophil cell 
death may also provide a therapeutic inflammatory prore-
solution strategy, although the effectiveness of this in the 
presence of defective clearance must be investigated. Another 
approach to promoting the resolution of inflammation is the 
therapeutic use of molecules that mimic the actions of potent 
endogenous proresolving mediators such as the lipid mediator 
resolvin E1.131 Such therapies are currently under develop-
ment, including the resolvin E1 mimetic (Resolvyx™); 
however, their potential therapeutic application in COPD 
has yet to be investigated.
Summary
GCs are not effective at controlling the chronic inflammatory 
response in COPD. This persistent and abnormal inflamma-
tion in the lung increases as the disease progresses. To date, 
there are no effective treatments to control this persistent 
inflammatory response and the associated decline of lung 
function of COPD. This is largely due to a lack of under-
standing the nature of the inflammatory response in COPD 
and the impact of key underlying factors such as oxidative 
stress on this inflammatory response.
It is clear that an effective anti-inflammatory therapy is 
likely to play a central role in the effective management of the 
disease in the future. It is therefore critical that we understand 
the mechanism of the abnormal inflammatory response in 
COPD, including the defective ability of GC-activated GRα 
to repress proinflammatory responses. Therapeutic targeting 
is likely to involve the oxidant-mediated alterations in kinase 
signaling and protein function, such as p38 MAPK, PI3Kδ, 
and GRα corepressors including HDAC-2. A more detailed 
elucidation of these pathways is needed before selected tar-
gets can be identified. In addition, agents that can restore GC 
sensitivity could be developed through an understanding of 
oxidant stress effects on GRs and signaling pathways. Some 
of these agents may also confer effective anti-inflammatory 
effects in COPD themselves. Finally, given the lack of 
successful anti-inflammatory drugs for COPD, a combina-
tion therapy directed in tandem against other aspects of the 
inflammatory response such as antioxidants and proresolving 
therapies may prove to be more effective at controlling the 
inflammation and thereafter halting the decline of both lung 
function and disease progression.
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